Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Myovant Sciences Ltd. (MYOV) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/20/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
03/17/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/17/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/10/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/10/2023 4 Valente Nancy (Director) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed/sold 3,673 shares @ $0
Disposed/sold 36,892 options to buy @ $22.71, valued at $837.8k
03/10/2023 4 POTTER MYRTLE S (Director) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed/sold 3,673 shares @ $0
Disposed/sold 45,000 options to buy @ $26.17, valued at $1.2M
Disposed/sold 58,608 options to buy @ $7.65, valued at $448.4k
Disposed/sold 21,603 options to buy @ $21.47, valued at $463.8k
Disposed/sold 21,096 options to buy @ $22.71, valued at $479.1k
03/10/2023 4 Merendino Lauren (Chief Commercial Officer) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed/sold 21,791 shares @ $0
Disposed/sold 147,747 shares @ $0
Disposed/sold 123,300 options to buy @ $17.88, valued at $2.2M
Disposed/sold 103,703 rights @ $0
03/10/2023 4 Mehra Uneek (Principal Financial Officer) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed/sold 20,724 shares @ $0
Disposed/sold 181,972 shares @ $0
Disposed/sold 165,192 options to buy @ $21.83, valued at $3.6M
Disposed/sold 111,111 rights @ $0
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/10/2023 4 Marek David C (Principal Executive Officer) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed/sold 95,675 shares @ $0
Disposed/sold 321,924 shares @ $0
Disposed/sold 306,427 options to buy @ $20.54, valued at $6.3M
Disposed/sold 208,218 options to buy @ $17.88, valued at $3.7M
Disposed/sold 204,808 options to buy @ $11.33, valued at $2.3M
Disposed/sold 134,567 rights @ $0
03/10/2023 SC 13D/A Sumitomo Chemical Co., Ltd. reports a 100% stake in Myovant Sciences Ltd.
03/10/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/10/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/10/2023 4 Lang Matthew (General Counsel & Corp. Secy.) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed/sold 113,145 shares @ $0
Disposed/sold 241,158 shares @ $0
Disposed/sold 220,000 options to buy @ $7.78, valued at $1.7M
Disposed/sold 87,050 options to buy @ $7.78, valued at $677.2k
Disposed/sold 152,110 options to buy @ $7.78, valued at $1.2M
Disposed/sold 170,396 options to buy @ $8.08, valued at $1.4M
Disposed/sold 90,310 options to buy @ $17.88, valued at $1.6M
Disposed/sold 111,111 rights @ $0
03/10/2023 4 Gulfo Adele M. (Director) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed/sold 3,673 shares @ $0
Disposed/sold 45,000 options to buy @ $11.17, valued at $502.7k
Disposed/sold 21,603 options to buy @ $21.47, valued at $463.8k
Disposed/sold 21,096 options to buy @ $22.71, valued at $479.1k
03/10/2023 4 GUINAN MARK (Director) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed/sold 3,673 shares @ $0
Disposed/sold 45,000 options to buy @ $19.71, valued at $887k
Disposed/sold 58,608 options to buy @ $7.65, valued at $448.4k
Disposed/sold 21,603 options to buy @ $21.47, valued at $463.8k
Disposed/sold 21,096 options to buy @ $22.71, valued at $479.1k
03/10/2023 4 Curran Terrie (Director) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed/sold 3,673 shares @ $0
Disposed/sold 33,846 options to buy @ $11.3, valued at $382.5k
Disposed/sold 11,154 options to buy @ $12.68, valued at $141.4k
Disposed/sold 22,500 options to buy @ $13.14, valued at $295.7k
Disposed/sold 22,500 options to buy @ $24.25, valued at $545.6k
Disposed/sold 5,250 options to buy @ $7.65, valued at $40.2k
Disposed/sold 21,603 options to buy @ $21.47, valued at $463.8k
Disposed/sold 21,096 options to buy @ $22.71, valued at $479.1k
03/10/2023 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
03/10/2023 4 Arjona Ferreira Juan Camilo (Chief Medical Officer) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed/sold 86,602 shares @ $0
Disposed/sold 160,082 shares @ $0
Disposed/sold 155,300 options to buy @ $7.78, valued at $1.2M
Disposed/sold 63,717 options to buy @ $7.78, valued at $495.7k
Disposed/sold 65,863 options to buy @ $7.78, valued at $512.4k
Disposed/sold 134,464 options to buy @ $8.08, valued at $1.1M
Disposed/sold 79,472 options to buy @ $17.88, valued at $1.4M
Disposed/sold 103,703 rights @ $0
03/10/2023 4 Sumitomo Chemical Co., Ltd. (10% Owner) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Bought 51,599,200 shares @ $27, valued at $1393.2M
03/10/2023 8-K Appointed a new director
Docs: "BERMUDA THE COMPANIES ACT 1981 MEMORANDUM OF ASSOCIATION OF COMPANY LIMITED BY SHARES",
"AMENDED AND RESTATED BYE-LAWS OF Myovant Sciences Ltd. Bermuda Office Canon’s Court 22 Victoria Street Hamilton HM 12 Bermuda CONTENTS Bye-Law Page Interpretation 1 General Meetings 3 Notice of General Meetings 3 Proceedings at General Meetings 4 Voting 5 Proxies and Corporate Representatives 6 Written Resolutions of the Sole Member 8 Appointment and Removal of Directors 8 Register of Directors and Officers 9 Resignation and Disqualification of Directors 9 Alternate Directors 9 Directors’ Fees and Expenses 10 Directors’ Interests 10 Role and Powers of the Board 11 Proceedings of the Board 12 Officers 14 Secretary and Resident Representative 14 Issue of Shares 14 Purchase of Shares 15 Variation of Share Rights 15 Share Certificates 15 Non-Recognition of Trusts 16 Lien 16 Calls on Shares 17 ...",
"NEW YORK and BASEL, Switzerland, March 10, 2023"
03/06/2023 SC 13D/A Sumitomo Chemical Co., Ltd. reports a 51.5% stake in Myovant Sciences Ltd.
03/06/2023 4 Sumitomo Chemical Co., Ltd. (10% Owner) has filed a Form 4 on Myovant Sciences Ltd.
Txns: Disposed of 4,243,005 shares @ $0
Acquired 1 options to buy @ $27, valued at $27
03/01/2023 8-K Quarterly results
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy